Standard BioTools Inc [NASDAQ: LAB] stock went on an upward path that rose over 2.42% on Tuesday, amounting to a one-week price increase of more than 7.17%.
Over the last 12 months, LAB stock rose by 43.50%. The one-year Standard BioTools Inc stock forecast points to a potential upside of 29.05. The average equity rating for LAB stock is currently 1.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $972.95 million, with 383.05 million shares outstanding and 369.07 million shares in the current float. Compared to the average trading volume of 2.37M shares, LAB stock reached a trading volume of 5695628 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Standard BioTools Inc [LAB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LAB shares is $3.58 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LAB stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
TD Cowen have made an estimate for Standard BioTools Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on April 16, 2024. While these analysts kept the previous recommendation, Jefferies raised their target price to Buy. The new note on the price target was released on April 04, 2024, representing the official price target for Standard BioTools Inc stock. Previously, the target price had yet another raise to $4, while KeyBanc Capital Markets analysts kept a Overweight rating on LAB stock.
The Average True Range (ATR) for Standard BioTools Inc is set at 0.14, with the Price to Sales ratio for LAB stock in the period of the last 12 months amounting to 7.68. The Price to Book ratio for the last quarter was 1.67, with the Price to Cash per share for the same quarter was set at 1.21.
LAB Stock Performance Analysis:
Standard BioTools Inc [LAB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.17. With this latest performance, LAB shares dropped by -8.30% in over the last four-week period, additionally plugging by 16.51% over the last 6 months – not to mention a rise of 43.50% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LAB stock in for the last two-week period is set at 51.58, with the RSI for the last a single of trading hit 55.44, and the three-weeks RSI is set at 50.47 for Standard BioTools Inc [LAB]. The present Moving Average for the last 50 days of trading for this stock 2.61, while it was recorded at 2.41 for the last single week of trading, and 2.43 for the last 200 days.
Insight into Standard BioTools Inc Fundamentals:
Standard BioTools Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.17 and a Current Ratio set at 4.50.
Standard BioTools Inc [LAB] Institutonal Ownership Details
The top three institutional holders of LAB stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in LAB stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in LAB stock with ownership which is approximately 5.8386%.
